AXIM Biotechnologies, Inc., a preclinical stage research and development company focuses on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). The company is developing NeuCovix, a rapid diagnostic test measuring levels of functional neutralizing antibodies to prevent SARS-CoV-2 from entering the host cells; and ImmunoPass, a rapid serological diagnostic test that measures SARS-CoV-2 neutralizing antibodies within 10 minutes. It is also developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is headquartered in San Diego, California.